Immunotherapy with checkpoint inhibitors of PD-1/PD-L1 monoclonal antibodies, has profoundly changed the treatment and efficacy in patients with non-small cell lung cancer (NSCLC) (1–4). Here, CD274 is linked to non-small cell lung carcinoma.